

In Silico Pharmacokinetic and Toxicity Analysis on Clitoria Ternatea Flower

by 1 1

Submission date: 29-Nov-2023 04:59PM (UTC+0200)

Submission ID: 2241969012

File name: Artikel-1_Revision_2190-8196-1-5-20230930.docx (254.09K)

Word count: 5590

Character count: 32085

In Silico Pharmacokinetic and Toxicity Analysis on *Clitoria Ternatea* Flower

Erna Yovi Kurniawati^{1*}, Noor Pramono², Syarif Taufik Hidayat², Endang Mahati³

¹Doctoral Program Medical and Health Sciences, Faculty of Medicine, Diponegoro University, Indonesia

²Department Fertility and Endocrinology, Faculty of Medicine, Diponegoro University, Indonesia

³Department Pharmacology and Therapy, Faculty of Medicine, Diponegoro University, Indonesia

Article Info

Article history:

Received mm dd, yyyy

Revised mm dd, yyyy

Accepted mm dd, yyyy

Keywords:

Clitoria Ternatea

In Silico

Pharmacokinetics

Toxicity

ABSTRACT

This article presents a pharmacokinetic analysis and in silico toxicity analysis of the flower of *C. ternatea*. *C. ternatea*, also known as "the butterfly flower," has long been used in traditional medicine and has significant pharmacological potential. In this study, we used computational methods to understand how the active compounds in the flower of *C. ternatea* can interact in the human body.

Study to predicted pharmacokinetic properties, including solubility, human intestinal absorption, distribution in the body, metabolism, and excretion. The results of this analysis provide insight into the potential of the compounds in the flower of *C. ternatea* as effective pharmacological agents. In addition, we also conducted an in silico toxicity assessment to identify the possible negative effects of these compounds on the human body.

The results of this research can provide a basis for the further development of the flowers of *C. ternatea* as a potential source for treatment and therapy. The results showed that most compounds have good bioavailability potential. Correlations between chemical structure and prediction of important parameters such as lipophilicity and P-gp substrate status were also explored. *C. ternatea* contains a compound with good pharmacological potential, but further research and experimental validation are needed to fully understand the pharmacologic and toxic properties of these compounds.

This is an open access article under the [CC BY-SA](#) license.



Corresponding Author:

Erna Yovi Kurniawati

Doctoral Program Medical and Health Sciences, Diponegoro University

Jl. Prof. Dr. Soedarto, Tembalang Semarang Jawa Tengah

Email: yovi.raharjanto@gmail.com

1. INTRODUCTION

C. ternatea is a plant that has a long history of being used as a natural source of ingredients for a variety of health purposes. *C. ternatea* extract has potential pharmacological benefits, which have attracted the interest of academics and practitioners of traditional medicine. The compounds found in the flower are phenols, terpenoids, fatty acids, alkaloids, cyclotides, and vitamins[1], [2]. *C. ternatea* has a water content of 92.4%, the predominant component is fat, accounting for (32.9%), carbohydrates (29.3%), fiber (27.6%), and protein (4.2%). In addition, *C. ternatea* also contain calcium 3.09 mg/g, magnesium 2.23, potassium 1.25, zinc 0.59, sodium, and iron 0.14 mg/g, respectively[2], [3].

The flavonoids in *C. ternatea* consist of 87% of the flavonols (caempferol, quercetin, myricetin, and isorhamnetin)[4]. Anthocyanidins: 27% (ternatin A1-A3, B1-B4, C1-C5, D1-D3, petunidin, peonidin, delphinidin, malvidin, cyanidin)[5]. Flavanols (epicatechin) and flavones (scutellarin, baicalein, luteolin, and apigenin)[3]. Phenolic acid consists of chlorogenic, protocatechuic, and gallic acids[6]. Terpenoids (triterpenoid and taraxerol), tocopherol saponins (alpha and gamma tocopherols), and phytosterols (campesterol, stigmasterol, beta-sitosterol, and sitostanol)[7]. Fatty acids (palmitic, stearic, petroselinic, linoleic, arachidic, behenic, and phytanic)[8], alkaloid content (3-deoxy-3, 11-epoxy cephalotaxine)[9], and vitamins (inositol and pentanal)[2].

This content makes *C. ternatea* a promising natural ingredient in the field of medicines and health supplements. However, the study of the use of *C. ternatea* as a potential drug requires understanding related pharmacokinetic profiles and toxicity using in silico methods such as Swiss ADME and Prottox II, as well as further validation through laboratory tests.

Pharmacokinetic analysis is correlate to bioavailability which can affect the pharmacology effect and the toxic effects of *C. ternatea* extract[10]. Conventional laboratory trials, however, can be expensive and time-consuming for pharmacokinetic and toxicity studies. As a result, we will use the in silico method with the Swiss ADME and Prottox II programs in this study. The pharmacokinetics of a substance, including the processes of absorption, distribution, metabolism, and excretion, can be estimated with the help of software called Swiss ADME. Prottox II is a toxicity predictor to assess the potential of chemical poisoning.

The objective of this study is to predict the potential pharmacological effects of *C. ternatea* extract so that it can study important details about how *C. ternatea* extract interacts with the human body, how the active ingredients are distributed within the body, and the potential toxic effects that may be caused by using the in silico method. The results of this research will further explain the potential applications of *C. ternatea* extracts as medications. The silico approach used in this study can also offer a faster and more cost-efficient alternative to understanding the pharmacokinetic properties and toxicity of natural compounds. The findings of this analysis could serve as a starting point for further research and potential advances in the pharmaceutical industry and the use of local wisdom as a herbal medicine.

2. METHOD

3D and Canonical SMILES structures were identified through the PubChem Database (National Library of Medicine). Analyze of the physiochemical descriptor as well as predict ADME parameters and drug-like properties (druglikeness) using SwissADME (Swiss Institute of Bioinformatics). Website Access <http://www.swissadme.ch>; upload SMILES compounds, SwissADME will provide results and ADME parameters. Toxicity of compounds tested using ProTox II (Prediction of Toxicity of Chemicals). Website Access https://tox-new.charite.de/protox_II/; upload SMILES compounds, select any additional models to predict and start Tox-Prediction. The dose of toxicity is based on LD50 in mg/kg of body weight. LD50 is a median lethal dose, which means a dose at which 50% of the test subjects die after exposure to a compound.

The toxicity class is determined by the globally harmonised chemical labeling classification system (GHS). The LD50 value is given in mg/kg. Class I: fatal if swallowed ($LD50 \leq 5$). Class II: lethal if swelled ($5 < LD50 \leq 50$). Class III: toxic if swalled ($50 < LD50 \leq 300$). Class IV: hazardous if swelled ($300 < LD50 \leq 2000$). Class V: may be hazardous if swollen ($2000 < LD50, \leq 5000$). Class VI: non-toxic ($LD50 > 5000$). Toxicity models analyze target hepatotoxicities, carcinogenicity, mutagenicity, and cytotoxics[10], [11]

3. RESULT and DISCUSSION

The solubility and bioavailability potential of a chemical compound in the human body are based on Lipinski's Rule. Lipinski's rule consists of four simple criteria that must be met by the chemical to be considered to have the potential to be a drug with good bioavailability, including: molecular weight less than 500 g/mol, Log P (octanol-water partition coefficient) less than 5, the number of hydrogen receptor atom donors from a bound hydrogen bond is less than or equal to 5, and the number of receptors of a hydrogen atom donor from a bonded hydrogen is less than or equivalent to 10. A compound meets at least four of the above criteria, so it is assumed that it has the potential to have good solubility in water and can easily pass through cell membranes. Compounds that meet Lipinski's Rule tend to have higher bioavailability, which means they are more likely to be absorbed by the body and produce the desired pharmacological effects[11], [12].

Table 1. Druglikeness *Clitoria Ternatea* Compounds

| Compound | Lipinski's Rule Parameter | | | | Druglikeness (Lipinski) |
|-------------|-----------------------------|-------------------|--------------------------------|----------------------------|-------------------------|
| | Molecular Weight ≤ 500 | MLOGP ≤ 4.15 | Num H-bond acceptors ≤ 10 | Num H-bond donors ≤ 5 | |
| Kaempferol | 286.24 g/mol | -0.03 | 6 | 4 | Yes |
| Quercetin | 302.24 g/mol | -0.56 | 7 | 5 | Yes |
| Myricetin | 318.24 g/mol | -1.08 | 8 | 6 | Yes |
| Ternatin | 374.34 g/mol | -0.12 | 8 | 2 | Yes |
| Petunidin | 317.27 g/mol | 0.03 | 7 | 5 | Yes |
| Peonidin | 301.27 g/mol | 0.57 | 6 | 4 | Yes |
| Delphinidin | 338.70 g/mol | 0.03 | 7 | 6 | Yes |
| Malvidin | 331.30 g/mol | 0.28 | 7 | 4 | Yes |
| Cyanidin | 287.24 g/mol | 0.32 | 6 | 5 | Yes |
| Epicatechin | 290.27 g/mol | 0.24 | 6 | 5 | Yes |
| Scutellarin | 462.36 g/mol | -2.12 | 12 | 7 | No |
| Baicalein | 270.24 g/mol | 0.52 | 5 | 3 | Yes |

| Compound | Lipinski's Rule Parameter | | | | Druglikeness (Lipinski) |
|-----------------------------------|---------------------------|-------------|--------------------------|----------------------|-------------------------|
| | Molecular Weight ≤500 | MLOGP ≤4.15 | Num H-bond acceptors ≤10 | Num H-bond donors ≤5 | |
| Luteolin | 286.24 g/mol | -0.03 | 6 | 4 | Yes |
| Apigenin | 270.24 g/mol | 0.52 | 5 | 3 | Yes |
| Chlorogenic | 354.31 g/mol | -1.05 | 9 | 6 | Yes |
| Protocatechuic | 154.12 g/mol | 0.40 | 4 | 3 | Yes |
| Gallic | 170.12 g/mol | -0.16 | 5 | 4 | Yes |
| Anthraquinone | 208.21 g/mol | 1.86 | 2 | 0 | Yes |
| Taraxerol | 426.72 g/mol | 6.92 | 1 | 1 | Yes |
| Alpha Tocopherol | 430.71 g/mol | 6.14 | 2 | 1 | Yes |
| Gamma-Tocopherol | 416.68 g/mol | 5.94 | 2 | 1 | Yes |
| Campesterol | 400.68 g/mol | 6.54 | 1 | 1 | Yes |
| Stigmasterol | 412.69 g/mol | 6.62 | 1 | 1 | Yes |
| Beta-Sitosterol | 414.71 g/mol | 6.73 | 1 | 1 | Yes |
| Sitosterol | 416.72 g/mol | 6.88 | 1 | 1 | Yes |
| Palmitic Acid | 256.42 g/mol | 4.19 | 2 | 1 | Yes |
| Stearic Acid | 284.48 g/mol | 4.67 | 2 | 1 | Yes |
| Petroselinic Acid | 282.46 g/mol | 4.57 | 2 | 1 | Yes |
| Linoleic Acid | 280.45 g/mol | 4.47 | 2 | 1 | Yes |
| Arachidic Acid | 312.53 g/mol | 5.13 | 2 | 1 | Yes |
| Behenic Acid | 340.58 g/mol | 5.58 | 2 | 1 | Yes |
| Phytanic Acid | 312.53 g/mol | 5.13 | 2 | 1 | Yes |
| 3-deoxy-3, 11-epoxy cephalotaxine | 313.35 g/mol | 1.56 | 5 | 0 | Yes |

Substance has a molecular weight greater than 500 and the log of the octanol/water partition coefficient (log P) is greater than +5, then the substance is impermeable and has low permeability. Groups O-H and N-H larger than 5 represent a donor of hydrogen binding (HBD), and the number of atoms O and N greater than 10 indicates a hydrogen-binding acceptor (HBA)[12]. Based on the above table, there is one compound with a status of no based on drug similarity based on Lipinski: a composite of scutellarine with a hydrogen binding donor > 5 is 7, and a receptor > 10 is 12. As for 33 other compounds, it is predictable that they meet the Lipinski Five Law, are readily absorbable, and have good permeability.

Forecasting absorption, distribution, metabolism, and excretion is then done by entering the SMILES code of the compound through the ADME Tools (Swiss ADME).

Table 2. ADME Prediction Analysis (Absorption, Distribution, Metabolism, Excretion)

| Compounds | ADME Prediction | | | | |
|------------|--------------------|--|------------------------------------|----------------------------|----|
| | Absorption | Distribution (Lipophilicity-Log P _{o/w}) | Metabolism (Cytochrome metabolism) | Excretion (P-gp substrate) | |
| Kaempferol | High GI Absorption | -6.7 Skin permeation (Log Kp) | 1.58 | CYP1A2 CYP2D6 CYP3A4 | No |
| Quercetin | High | -7.05 | 1.23 | CYP1A2 CYP2D6 CYP3A4 | No |
| Myricetin | Low | -7.4 | 0.79 | CYP1A2 CYP3A4 | No |
| Ternatin | High | -6.37 | 2.50 | CYP1A2 | No |

| Compounds | ADME Prediction | | | | |
|----------------------------------|------------------|--------------------------------|---|--|----------------------------------|
| | Absorption | | Distribution (Lipophilicity- Log P _{o/w}) | Metabolism (Cytochrome metabolism) | Excretion (P-gp substrate) |
| | GI Absorption | Skin permeation (Log Kp) | | | |
| | | | | CYP2C9 CYP3A4 | |
| Petunidin | High | -6.88 | 0.63 | CYP1A2 | Yes |
| Peonidin | High | -6.53 | 0.97 | CYP1A2 | Yes |
| Delphinidin | High | -7.5 | -0.98 | No | Yes |
| Malvidin | High | -6.73 | 0.92 | CYP1A2 | Yes |
| Cyanidin | High | -7.51 | 0.32 | CYP1A2 | Yes |
| Epicatechin | High | -7.82 | 0.85 | No | Yes |
| Scutellarin | Low | -8.59 | -0.20 | No | Yes |
| Baicalein | High | -5.7 | 2.24 | CYP1A2 CYP2D6 | No |
| Luteolin | High | -6.25 | 1.73 | CYP3A4 CYP1A2 CYP2D6 | No |
| Apigenin | High | -5.8 | 2.11 | CYP3A4 CYP1A2 CYP2D6 | No |
| Chlorogenic | Low | -8.76 | -0.38 | No | No |
| Protocatechuic | High | -6.42 | 0.65 | CYP3A4 | No |
| Gallic | High | -6.84 | 0.21 | CYP3A4 | No |
| Anthraquinone | High | -5.16 | 2.64 | CYP1A2 CYP2C19 | No |
| Taraxerol | Low | -2.3 | 7.22 | No | No |
| Alpha Tocopherol | Low | -1.33 | 8.27 | No | Yes |
| Gamma-Tocopherol | Low | -1.51 | 7.95 | No | Yes |
| Campesterol | Low | -2.5 | 6.90 | No | No |
| Stigmasterol | Low | -2.74 | 6.97 | CYP2C9 | No |
| Beta-Sitosterol | Low | -2.2 | 7.19 | No | No |
| Sitostanol | Low | -2.93 | 7.07 | No | No |
| Palmitic Acid | High | -2.77 | 5.20 | CYP1A2 CYP2C9 | No |
| Stearic Acid | High | -2.19 | 5.93 | CYP1A2 | No |
| Petroselinic Acid | High | -2.6 | 5.70 | CYP1A2 CYP2C9 | No |
| Linoleic Acid | High | -3.05 | 5.45 | CYP1A2 CYP2C9 | No |
| Arachidic Acid | Low | -1.61 | 6.62 | CYP1A2 | No |
| Behenic Acid | Low | -1.01 | 7.40 | CYP1A2 | No |
| Phytanic Acid | High | -2.31 | 6.15 | CYP2C9 | Yes |
| 3-deoxy-3,11-epoxy cephalotaxine | High | -7.25 | 1.95 | CYP2D6 | No |

GI (gastrointestinal) absorption gives an estimate of the potential absorption of a compound through the digestive tract. High: If a compound is categorized as "high" in GI absorption, this indicates that the compound has a high potential for good absorption through the digestive tract. These compounds tend to be easily absorbed by the intestinal walls and enter the bloodstream. Moderate: If a compound is categorized as "moderate" in GI absorption, this indicates that the compounds have a potential for moderate or moderate absorptions through the digestive tract. The absorption rate of the compound may not be as efficient as "high," but it is also not as bad as low. Low: If a compound is categorized as "low" in GI absorptions, this indicates that the composition has a low gastrointestinal absorptive potential. Compounds in the "low" category may have a barrier to intestinal absorption, so a significant amount of such compounds may not be absorbed efficiently into the systemic circulation[11], [13].

Based on the ADME prediction table, the GI absorption prediction results are 22 compounds in the "high" category (kaempferol, quercetin, ternatin, petunidin, peonidin, delphinidin, malvidin, cyanidin, epicatechin, isorhamnetin, baicalin, luteolin, apigenin, protocatechuic, gallic, anthraquinone, palmitic acid, stearic acid, petroselinic acids, linoleic acids, phytanic acid, 3-deoxy-3, 11-epoxy cephalotaxine). There are 12 compounds in the category "low" (myricetin, scutellarin, chlorogenic, taraxerol, alpha-tocopherol, gamma-tocopherol, campesterol, stigmasterol, beta-sitosterol, sitostanol/mastanol, arachidic acid, and behenic acid). The GI absorption category is important in drug pharmacokinetics as it can affect the degree and duration of the effect of a drug in the body. Compounds with high GI absorption tend to have better bioavailability, which means they are more efficient in reaching the target tissue and producing the desired therapeutic effect[11], [12].

The octanol-water partition coefficient (Log K_p) is one of the parameters used to predict how far a compound can penetrate or absorb through the skin. Compounds with high skin permeation potential can affect drug administration route choices, such as transdermal or topical. Transdermal delivery allows the compound to penetrate the skin and reach the bloodstream without passing through the digestive tract, thus providing a more stable pharmacokinetic profile and avoiding excessive metabolism in the liver. In general, compounds with relatively high log K_p values are more likely to be developed as transdermal drugs than for topical applications. Topical application focuses on local effects on the surface area of the skin and does not require efficient absorption into the bloodstream[13], [14].

The level of skin permeability that is considered good for transdermal patches is usually in the range of about -3 to -1 cm/s. A higher level of permeability in this range indicates that the compound is more easily penetrating the skin and has the potential to provide an effective therapeutic dose. Compounds with a low log K_p value tend to remain on the skin surface without penetrating deeper. Compounds with a positive log K_p value (values above zero) tend to have the potential to penetrate or absorb through the skin better than compounds with a negative log K_p value (values below zero). A positive Log K_p value indicates that the compound is more prone to transitioning from the water (skin) phase to the non-polar phase (such as the skin layer)[11], [14]. There are 13 compounds that are predicted to be developed into transdermal patches of ternate clitoral, including taraxerol, alpha-tocopherol, gamma-tocopherol, campesterol, stigmasterol, beta-sitosterol, sitostanol/stigmastanol, palmitic acid, stearic acid, petroselinic acids, arachidic acids, behenic acid, and phytanic acid.

The Log P_{o/w} value is used to predict the extent to which a compound will dissolve in fat (hydrophobicity) and how easily such compounds can penetrate biological membranes, including the cell membrane, to reach biological or systemic

targets in the body. These measurements are used to understand how the composition behaves within the body and influences interactions with biological targets, as well as to design compounds with desired pharmacokinetic properties. If the Log Po/w value is positive (Log Po/w > 0), the compound has a higher affinity to be dissolved in octanols or fat solvents than water. This indicates the hydrophobic or lipophilic properties of the compound, which means that the compound is more soluble in the fat phase than the water phase. Compounds with a high Log Po/W value tend to be more readily penetrating through cell membranes and tissues, as well as having a higher probability of distribution in the fatty tissue and other non-polar organs. If the log Po/w value is negative (LOG PO/w < 0), such compounds have a greater affinity for dissolving in the water than the octanol or the fat solver, indicating the hydrofobic and lipophobic characteristics of the compound, meaning that such a composite is more likely to be solvent in the aquatic phase rather than the fat phase [11], [12], [14]

All compounds are lipophobic, except the three hydrophilic. (delphinidin, scutellarin, chlorogenic) One of the important elements in pharmacokinetics and drug effects on the body is lipophilia. Better membrane and biological tissue penetration is characteristic of compounds with high lipophilicity, which allows for more effective distribution to various organs and tissues of the body. However, excessive lipophilization can also lead to an accumulation of substances in certain fat tissues and organs, which can affect the way the body distributes and removes those substances. Therefore, determining lipophilicity is an important component of pharmaceutical research and drug design [13].

Cytochrome metabolism is an important biochemical process in the human body involving the enzyme cytochrome P450, which is responsible for the breakdown and modification of compounds in the body. Information about the possible cytochrome metabolism of various compounds in natural substances such as C. ternatea can help understand how these compounds are processed by the body and their potential to interact with drugs or other substances. Some compounds, such as kaempferol, quercetin, ternatin, petunidin, peonidin, malvidin, and cyanidin, have predictions of metabolism by the CYP1A2 enzyme, which is one of the most active cytochrome P450 enzymes in the human body, suggesting that these compounds may undergo significant breakdown and modification in the body. The compounds baicalein, luteolin, and apigenin have predictions of metabolism by CYP2D6 and cYP3A4, which are other P450 cytochrome enzymes that are important in the breakdown of different compounds [14].

However, some compounds, such as delphinidine, epicatechin, scutellarin, chlorogenic, alpha-tocopherol, gamma-tocopherol, taraxerol, and a number of other compounds, have no prediction of metabolism by a particular cytochrome P450 enzyme. This may indicate that these compounds are less susceptible to breakdown in the body by these enzymes. Understanding the metabolism of these natural compounds can have an impact on the development of new medicines or health supplements, as well as a further understanding of how these natural substances can affect human health. Although this is an initial prediction, this information could serve as a basis for further research on the potential health effects of these natural compounds [14].

P-gp (P-glycoprotein) is an active transport protein found in the cell membranes of many organs, including the intestines, liver, kidneys, and brain. Drug pharmacokinetics and therapeutic outcomes can be affected by Pgp interactions. When a substance that is a Pgp substrate interacts with Pgp, there will be an increase in elimination from target tissue or a decrease in levels in the bloodstream, which reduces the expected therapy effect. Furthermore, some substances that inhibit Pgp

activity can increase the level of Pgp substrates in the body, which can result in drug interactions and a higher risk of side effects. When considering potential drug interactions or pharmacokinetic problems that may arise from the use of several drugs at once, it is important to know the status of the Pgp compound when designing the drug and providing patient care[14], [15].

There are 10 compounds (peonidin, delphinidin, malvidin, petunidin, cyanidin, epicatechin, scutellarin, alpha-tocopherol, gamma-tocopherol, and phytanic acid) with Pgp substrate status "yes", as well as 24 compounds with "no" status. For Pgp substrates with "no" status, it can be understood that the compounds evaluated in the analysis are not considered P-glycoprotein (Pgp) substrates. These compounds have little or no affinity to interact with Pgp and will not undergo elimination or a decrease in the level of the target cell protein by Pgp. The compounds are predicted to have no significant interaction with Pgp, and therefore, their transportation out of the cell by Pgp is not a problem to be taken into account in its pharmacokinetic or pharmacological effects. This can be useful information in pharmaceutical design because they do not have a substratum in the body that can be regarded as a bio-distributed substrated substrates[13]-[15].

A Pgp substrate with "yes" status means that the compound evaluated in the analysis is considered to be a P-glycoprotein (Pgp) substrate. Such compounds have an affinity to interact with Pgp and are likely to experience elimination or reduction of the level of target cells by the Pgp protein. Pgp is an active transport protein that removes foreign compounds, including drugs, from cells into the lumen of the intestine, bile, or urine. If a compound is a Pgp substrate, there may be a decrease in the concentration of active compounds in the blood or target tissue as a result of elimination by Pgp. Interactions with Pgp can have important implications for drug design and patient treatment, especially when using drugs simultaneous. Compounds that are Pgp substrats may experience pharmacokinetic changes when interacting with Pgp, or if there are other drugs that cause inhibition or induction of Pgp, this may affect the required dosage, therapeutic effects, or the possibility of unwanted drug interactions[13], [14].

The ability of a compound or substance to harm living creatures is known as toxicity. The level of toxicity of a substance is determined by general toxicities, which include natural substances found in plants, animals, and other natural resources. The toxicity of natural compounds, including hepatotoxicity, carcinogenicity, mutagenicity, and cytotoxics, is critical for many pharmaceutical, medical, and environmental applications. Toxicity testing of compounds from natural ingredients is crucial because it can help in identifying potentially hazardous or toxic substances and provide guidance for safe and effective drug design [15], [16]

Table 3. Toxicity Test Results of *Clitoria Ternatea* Compound

| Compounds | LD50 (mg/kg) | Toxicity Class | Toxicity | | | | |
|-------------|--------------|----------------|----------------|-----------------|----------------|--------------|--------------|
| | | | Hepatotoxicity | Carcinogenicity | Immunotoxicity | Mutagenicity | Cytotoxicity |
| Kaempferol | 3919 | 5 | Inactive | Active | Inactive | Active | Inactive |
| Quercetin | 159 | Missing | Inactive | Active | Inactive | Active | Inactive |
| Myricetin | 159 | Missing | Inactive | Active | Inactive | Active | Inactive |
| Ternatin | 5000 | 5 | Inactive | Inactive | Active | Inactive | Inactive |
| Petunidin | 5000 | 5 | Inactive | Active | Active | Inactive | Inactive |
| Peonidin | 5000 | 5 | Inactive | Inactive | Inactive | Inactive | Inactive |
| Delphinidin | 5000 | 5 | Inactive | Inactive | Inactive | Inactive | Inactive |
| Malvidin | 5000 | 5 | Inactive | Inactive | Active | Missing | Inactive |
| Cyanidin | 5000 | 5 | Inactive | Active | Inactive | Inactive | Inactive |
| Epicatechin | 10000 | Missing | Inactive | Inactive | Inactive | Inactive | Inactive |

| Compounds | LD50 (mg/kg) | Toxicity Class | Toxicity | | | | |
|-----------------------------------|--------------|----------------|----------------|-----------------|----------------|--------------|--------------|
| | | | Hepatotoxicity | Carcinogenicity | Immunotoxicity | Mutagenicity | Cytotoxicity |
| Scutellarin | 5000 | 5 | Inactive | Active | Sp. Inactive | Sp. Inactive | Inactive |
| Baicalein | 3919 | 5 | Inactive | Active | Inactive | Missing | Active |
| Luteolin | 3919 | 5 | Inactive | Inactive | Inactive | Missing | Inactive |
| Apigenin | 2500 | 5 | Inactive | Inactive | Inactive | Missing | Inactive |
| Chlorogenic | 5000 | 5 | Inactive | Inactive | Active | Missing | Inactive |
| Protocatechuic | 2000 | 4 | Inactive | Active | Inactive | Inactive | Inactive |
| Gallic | 2000 | 4 | Inactive | Active | Inactive | Inactive | Missing |
| Anthraquinone | 5000 | 5 | Inactive | Inactive | Missing " | Inactive | Active |
| Taraxerol | 70000 | 6 | Inactive | Inactive | Active | Inactive | Inactive |
| Alpha Tocopherol | 5000 | 5 | Inactive | Inactive | Inactive | Inactive | Inactive |
| Gamma-Tocopherol | 5000 | 5 | Inactive | Inactive | Inactive | Inactive | Inactive |
| Campesterol | 890 | 4 | Inactive | Inactive | Active | Inactive | Inactive |
| Stigmasterol | 890 | 4 | Inactive | Inactive | Active | Missing | Inactive |
| Beta-Sitosterol | 890 | 4 | Inactive | Inactive | Missing " | Active | Inactive |
| Sitostanol | 500 | 4 | Inactive | Inactive | Active | Missing | Inactive |
| Palmitic Acid | 900 | 4 | Inactive | Inactive | Inactive | Inactive | Inactive |
| Stearic Acid | 900 | 4 | Inactive | Inactive | Inactive | Inactive | Inactive |
| Petroselinic Acid | 48 | 2 | Inactive | Inactive | Inactive | Inactive | Inactive |
| Linoleic Acid | 100000 | 6 | Inactive | Inactive | Inactive | Inactive | Inactive |
| Arachidic Acid | 900 | 4 | Inactive | Inactive | Inactive | Inactive | Inactive |
| Behenic Acid | 900 | 4 | Inactive | Inactive | Inactive | Inactive | Inactive |
| Phytanic Acid | 900 | 4 | Inactive | Inactive | Inactive | Inactive | Inactive |
| 3-deoxy-3, 11-epoxy cephalotaxine | 28 | 2 | Inactive | Active | Active | Missing " | Inactive |

A huge amount of research and toxicity testing should be done on any natural ingredient intended to be used in pharmaceutical products, food supplements, or medicines. Toxicity studies help determine safe doses and help in the development of products that are safe for human health. Compounds found in natural products can vary in toxicity depending on their chemical and biological properties. Plants that are traditionally used as medicines contain compounds with low toxicity or even beneficial effects on health, but certain ingredients of natural products can also be highly toxic and harmful to humans[15].

The results of the analysis showed large variations in the LD50 of various compounds, with the highest value being 100,000 mg/kg (linoleic acid) and the lowest being 28 mg/kg. (3-deoxy-3, 11-epoxy cephalotaxine). Test results of LD50 compounds petroselinic acid and 3-deoxy-3, 11-epoxy cephalotaxine in class 2 compounds with LD50 class 2 considered to be toxic with high potential to cause negative effects on test organisms in moderate doses. These compounds have the ability to cause damage or disruption to the body's functions when consumed or exposed in sufficiently high doses. The LD50 test results of compounds in class 3 are quercetin and myricetin. Compounds with class 3 LD50 are considered to be toxic, with a moderate level of toxicity. Although its toxicity is lower than that of compounds with grade 1 and 2 LD50s, the compound still has the potential to cause negative effects on test organisms at higher doses. Even higher doses are needed to cause death in 50% of the test animals, but they still have the potential to cause toxic effects if swallowed in significant doses[16].

The LD50 test results of the compounds in class 4 are: protocatechuic, campesterol, stigmasterol, beta-sitosterol, sitostanol/stigmastanol, palmitic acid, stearic acid, arachidic acids, behenic acids, phytanic acid, and gallic acid. This classification suggests that much higher doses are needed to cause death or toxic effects, but we still need to be cautious as it can be dangerous if swallowed in significant doses. The LD50 test results of compounds in class 5 are: kaempferol, ternatin, sinensetin, peonidin, petunidin, delphinidin, malvidin, cyanidin, isorhamnetin, scutellarin, baicalein, luteolin, apigenin, chlorogenic, anthraquinone, alpha-tocopherol, and gamma-tocopherol. This category indicates that the compound has a low to moderate toxicity potential if swallowed. The doses required to cause toxicity effects in 50% of the test animals are within a sufficiently high range, so the compounds tend to be less harmful at doses commonly used in human applications or exposures. The LD50 test results of the compounds epicatechin, taraxerol, and linoleic acid fall into the class 6 category. Very high doses are required to cause toxicity effects, and this classification suggests that such a compound is considered non-toxic at commonly used doses. The majority of the compounds in *C. ternatea* are classified in classes 4 and 5, which show moderate to low levels of toxicity.[15], [16].

Analysis suggests that the compound *C. ternatea* is predicted to have no hepatotoxic activity, which can damage the liver. Some compounds are predicted to have carcinogenic potential, which means they can cause cancer. Compounds such as kaempferol, quercetin, myricetin, petunidin, cyanidin, scutellarin, baicalein, protocatechuic, gallic, and 3-deoxy-3, 11-epoxy cephalotaxine are classified as active in terms of carcinogenicity, so use or exposure to these compounds should be cautious. Some compounds are predicted to have immunotoxic potential, which can affect the immune system. These compounds, such as ternatin, petunidin, chlorogenic, taraxerol, campesterol, stigmasterol, beta-sitosterol, cytostanol, and 3-deoxy-3, 11-epoxy cephalotaxine, may affect the body's immune response to infection or disease. Mutagenicity refers to the ability of a compound to cause mutations in genetic material. Some compounds in this study are classified as active in terms of mutagenicity, such as kaempferol and quercetin, myricetin, baicalein, and anthraquinone, suggesting that these compounds can cause potentially harmful genetic changes. The compounds 3-deoxy-3, 11-epoxy cephalotaxine are predicted to have cytotoxic potential, which can affect the health of cells in the body. Further studies may be needed to confirm these predictions and identify more detailed toxic mechanism[15], [17].

Almost all the compounds in *C. ternatea* have a molecular weight that is well below the 500 g/mol limit recommended by Lipinski's Rule. A lower molecular weight tends to facilitate solubility in water and absorption by the body. Most of the compounds in *C. ternatea* have a negative log P value, showing their hydrophilic properties. Although some compounds, such as anthraquinone and taraxerol, have a positive log P value that shows higher hydrophobic qualities, this can affect the absorption and distribution of these compounds in the body. Compounds that have the potential to form more hydrogen bonds (more H-bond recipients and H-binders) have stronger interactions with molecules in the body. Most of the compounds in *C. ternatea* have a number of H-bonds that correspond to Lipinski's Rule criteria. Most compounds in *C. ternatea* have a high colon absorption prediction, which corresponds to predictions based on Log P parameters and a lower molecular weight, suggesting that these compounds have a good absorptive potential through the digestive tract. Some compounds, such as taraxerol, alpha-tocopherol, and gamma-tocopherol, have predictions of high levels of skin permeability, consistent with positive Log P values that indicate higher hydrophobic properties, making these compounds potential for use in transdermal formulations.

Some compounds in *C. ternatea* are predicted to undergo metabolism by various cytochrome P450 enzymes such as CYP1A2, CYP2D6, and CYP3A4, which can affect the rate of elimination and potential interactions with other drugs in the body. Some compounds in *C. ternatea* are predicted to be P-glycoprotein (P-gp) substrates, which can affect the elimination of target tissue and drug interactions. These compounds may require dose adjustments or consider potential drug interactions. Compounds with specific functional groups, such as phenol groups in kaempferol, quercetin, and others, can have certain toxic activities, including carcinogenic and mutagenic activity. Some compounds of certain functional groups can also have hepatotoxic or immunotoxic potential. In this analysis, predictions of physiochemical parameters can provide initial clues about the potential pharmacokinetic properties and toxicity of the compounds in *C. ternatea*. However, it is important to remember that these predictions still require further experimental validation to confirm these relationships and identify potential side effects or more detailed health benefits of these compounds. In addition, other factors such as dosage, administration route, and interaction with other compounds can also influence the body's response to these compounds.

4. CONCLUSION

The compounds in *C. ternatea* have a molecular weight that conforms to Lipinski's Rule, indicating good absorption potential. The hydrophobic properties of some compounds affect their distribution and permeability. Predicting metabolism and P-gp status provides insight into the pharmacokinetic effects. Experimental validation is required for confirmation.

5. ACKNOWLEDGEMENT

This journal article is written as preliminary research funded by the Ministry of Education, Culture, Research, and Technology through the Indonesian Educational Scholarship Program of the Doctoral Program. The content is entirely the responsibility of the author. The author wishes to state that there is no conflict of interest that may affect the outcome or interpretation in this article.

BIBLIOGRAPHY

- [1] E. J. Jeyaraj, Y. Y. Lim, and W. S. Choo, "Extraction methods of butterfly pea (*Clitoria ternatea*) flower and biological activities of its phytochemicals," *J Food Sci Technol*, vol. 58, no. 6, pp. 2054–2067, Jun. 2021, doi: [10.1007/S13197-020-04745-3/METRICS](https://doi.org/10.1007/S13197-020-04745-3/METRICS).
- [2] A. M. Marpaung, "Tinjauan manfaat bunga telang (*clitoria ternatea* l.) bagi kesehatan manusia," *Journal of Functional Food and Nutraceutical*, vol. 1, no. 2, pp. 63–85, Feb. 2020, doi: [10.33555/JFFN.V1I2.30](https://doi.org/10.33555/JFFN.V1I2.30).
- [3] W. F. Afrianto, F. TAMNGE, and L. N. HASANAH, "Review: A relation between ethnobotany and bioprospecting of edible flower Butterfly Pea (*Clitoria ternatea*) in Indonesia," *Asian Journal of Ethnobiology*, vol. 3, no. 2, Oct. 2020, doi: [10.13057/ASIANJETHNOBIOL/Y030202](https://doi.org/10.13057/ASIANJETHNOBIOL/Y030202).
- [4] N. F. A. M. Zian *et al.*, "Mapping Molecular Networks within *Clitoria ternatea* Linn. against LPS-Induced Neuroinflammation in Microglial Cells, with Molecular Docking and In Vivo Toxicity Assessment in Zebrafish," *Pharmaceuticals*, vol. 15, no. 4, p. 467, Apr. 2022, doi: [10.3390/PH15040467/S1](https://doi.org/10.3390/PH15040467/S1).
- [5] N. A. Binte and A. Poh, "Investigation of the Colour Changes of *Clitoria ternatea* in Different pH Conditions".
- [6] G. B. Escher, M. Wen, L. Zhang, N. D. Rosso, and D. Granato, "Phenolic composition by UHPLC-Q-TOF-MS/MS and stability of anthocyanins from *Clitoria ternatea* L. (butterfly pea) blue petals," *Food Chem*, vol. 331, p. 127341, Nov. 2020, doi: [10.1016/J.FOODCHEM.2020.127341](https://doi.org/10.1016/J.FOODCHEM.2020.127341).
- [7] A. A. Margret, V. Dhayabaran, S. Suvaitenamudhan, and S. Parthasarathy, "Analysing the antidepressant and drug efflux competence of *Clitoria ternatea* L. as P-glycoprotein inhibitor to facilitate blood brain barrier," *Acta Sci Biol Sci*, vol. 41, no. 1, p. e46629, Dec. 2019, doi: [10.4025/actascibiols.v41i1.46629](https://doi.org/10.4025/actascibiols.v41i1.46629).
- [8] R. R. Multisona, S. Shirodkar, M. Arnold, and A. Gramza-Michalowska, "Clitoria ternatea Flower and Its Bioactive Compounds: Potential Use as Microencapsulated Ingredient for Functional Foods," *Applied Sciences 2023*, Vol. 13, Page 2134, vol. 13, no. 4, p. 2134, Feb. 2023, doi: [10.3390/APP13042134](https://doi.org/10.3390/APP13042134).
- [9] M.- RAJAMANICKAM, "Isolation and Characterizations of new alkaloid 3-deoxy- 3, 11-epoxy cephalotaxine from *Clitoria ternatea*," *Journal of Drug Delivery and Therapeutics*, vol. 9, no. 4-A, pp. 458–462, Aug. 2019, doi: [10.22270/JDDT.V9I4-A.3472](https://doi.org/10.22270/JDDT.V9I4-A.3472).
- [10] K. Linggam, S. Ramanathan, S. Sasidharan, and S. M. Mansor, "Toxicity evaluation of methanol extract of *clitoria ternatea* L. Leaf," *Malaysian Journal of Medicine and Health Sciences*, vol. 8, no. 2, pp. 33–39, 2012, Accessed: Jun. 25, 2023. [Online]. Available: <https://www.researchgate.net/publication/288117872>



- [11] P. Rani, B. K. Rajak, and D. V. Singh, "Physicochemical parameters for design and development of lead herbicide molecules: Is 'Lipinski's rule of 5' appropriate for herbicide discovery?," *Pest Manag Sci*, vol. 79, no. 5, pp. 1931-1943, May 2023, doi: 10.1002/PS.7367.
- [12] R. Roskoski, "Rule of five violations among the FDA-approved small molecule protein kinase inhibitors," *Pharmacol Res*, vol. 191, p. 106774, May 2023, doi: 10.1016/j.phrs.2023.106774.
- [13] K. M. Al Azzam, "SwissADME and pkC_{SM} Webservers Predictors: an integrated Online Platform for Accurate and Comprehensive Predictions for In Silico ADME/T Properties of Artemisinin and its Derivatives," *Kompleksnoe Ispolzovanie Mineralnogo Syra = Complex use of mineral resources*, vol. 325, no. 2, pp. 14-21, Jun. 2023, doi: 10.31643/2023/6445.13.
- [14] B. Bakchi *et al.*, "An overview on applications of SwissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: A medicinal chemist's perspective," *J Mol Struct*, vol. 1259, p. 132712, Jul. 2022, doi: 10.1016/j.molstruc.2022.132712.
- [15] H. K. Shin, R. Huang, and M. Chen, "In silico modeling-based new alternative methods to predict drug and herb-induced liver injury: A review," *Food and Chemical Toxicology*, vol. 179, p. 113948, Sep. 2023, doi: 10.1016/j.fct.2023.113948.
- [16] E. Benfenati, Q. Chaudhry, G. Gini, and J. Lou Dorne, "Integrating in silico models and read-across methods for predicting toxicity of chemicals: A step-wise strategy," *Environ Int*, vol. 131, p. 105060, Oct. 2019, doi: 10.1016/j.envint.2019.105060.
- [17] P. K. P. Krishnamoorthy *et al.*, "In-silico study reveals immunological signaling pathways, their genes, and potential herbal drug targets in ovarian cancer," *Inform Med Unlocked*, vol. 20, p. 100422, Jan. 2020, doi: 10.1016/j.imu.2020.100422.



In Silico Pharmacokinetic and Toxicity Analysis on Clitoria Ternatea Flower

ORIGINALITY REPORT

19%

SIMILARITY INDEX

16%

INTERNET SOURCES

16%

PUBLICATIONS

12%

STUDENT PAPERS

PRIMARY SOURCES

| | | |
|---|---|----|
| 1 | Submitted to University College London Student Paper | 2% |
| 2 | www.mdpi.com Internet Source | 1% |
| 3 | Vincent A. Obakachi, Idowu Kehinde, Narva Deshwar Kushwaha, Olayinka I. Akinpelu et al. "Structural based investigation of novel pyrazole-thiazole Hybrids as dual CDK-1 and CDK-2 inhibitors for cancer chemotherapy", Molecular Simulation, 2022 Publication | 1% |
| 4 | kims-imio.com Internet Source | 1% |
| 5 | Submitted to Universitas Islam Bandung Student Paper | 1% |
| 6 | publicsafety.howard.edu Internet Source | 1% |
| 7 | ojs.pps.unsri.ac.id Internet Source | 1% |

| | | |
|----|--|------|
| 8 | www.atlantis-press.com Internet Source | 1 % |
| 9 | www.akademiabaru.com Internet Source | 1 % |
| 10 | Muhammad Sadaqat, Muhammad Qasim, Muhammad Tahir ul Qamar, Muhammad Shareef Masoud et al. "Advanced network pharmacology study reveals multi-pathway and multi-gene regulatory molecular mechanism of Bacopa monnieri in liver cancer based on data mining, molecular docking, and microarray data analysis", Computers in Biology and Medicine, 2023 Publication | 1 % |
| 11 | www.researchgate.net Internet Source | 1 % |
| 12 | publikasi.polije.ac.id Internet Source | <1 % |
| 13 | Hyun Kil Shin, Ruili Huang, Minjun Chen. "In silico modeling-based new alternative methods to predict drug and herb-induced liver injury: A review", Food and Chemical Toxicology, 2023 Publication | <1 % |
| 14 | M. Hernández-Mesa, B. Le Bizec, G. Dervilly. "Metabolomics in chemical risk analysis – A review", Analytica Chimica Acta, 2021 | <1 % |

| | | |
|----|---|------|
| 15 | downloads.hindawi.com Internet Source | <1 % |
| 16 | etheses.uin-malang.ac.id Internet Source | <1 % |
| 17 | Submitted to Maulana Azad National Institute of Technology Bhopal Student Paper | <1 % |
| 18 | www.grafiati.com Internet Source | <1 % |
| 19 | www.hindawi.com Internet Source | <1 % |
| 20 | www.frontiersin.org Internet Source | <1 % |
| 21 | Dina G. Sanad, Ahmed S. A. Youssef, Fatma A. El-Mariah, Heba E. Hashem. "Synthesis, Molecular Docking Study, and ADMET Properties of New Antimicrobial Quinazolinone and Fused Quinazoline Derivatives", Polycyclic Aromatic Compounds, 2022 Publication | <1 % |
| 22 | medicinus.co Internet Source | <1 % |
| 23 | Durgasha C. Poudyal, Vikram Narayanan Dhamu, Manish Samson, Sriram Muthukumar, | <1 % |

Shalini Prasad. "Pesticide analytical screening system (PASS): A novel electrochemical system for multiplex screening of glyphosate and chlorpyrifos in high-fat and low-fat food matrices", Food Chemistry, 2023

Publication

24

worldwidescience.org

Internet Source

<1 %

25

Elarbi Abderraouf, Mohamed Rida Lahcene, Sid Ahmed Zegnoun, Mohammed Sofiane Bendelhoum et al. "Transmission performance in compressed medical images using turbo code", Indonesian Journal of Electrical Engineering and Computer Science, 2022

Publication

<1 %

26

jpsr.pharmainfo.in

Internet Source

<1 %

27

ouci.dntb.gov.ua

Internet Source

<1 %

28

Sahar Saleh Alghamdi, Rasha Saad Suliman, Norah Abdulaziz Aljammaz, Khawla Mohammed Kahtani et al. "Natural Products as Novel Neuroprotective Agents; Computational Predictions of the Molecular Targets, ADME Properties, and Safety Profile", Plants, 2022

Publication

<1 %

29 journal.um-surabaya.ac.id <1 %
Internet Source

30 Astika Widy Utomo, Dwi Aris agung Nugrahaningsih, Iwan Dwiprahasto. "The effect of chronic usage of Renin-Angiotensin-Aldosterone System Blocking Agents on Incidence of Contrast-Induced Nephropathy in patients with Diabetes Mellitus and Renal Insufficiency. A Restropesctive Cohort Study", Indonesian Journal of Cardiology, 2019 <1 %
Publication

31 "Performance evaluation of classifiers for the COVID-19 symptom-based dataset using different feature selection methods", International Journal of Advanced Technology and Engineering Exploration, 2023 <1 %
Publication

32 Karin Ekman, Marisa Ponti, Marc Peñalver Grau, Nuria Castell, Rasmus Nedergård Steffansen, Enza Lissandrello. "Agency and responsibility in smart air pollution monitoring", 2023 8th International Conference on Smart and Sustainable Technologies (SpliTech), 2023 <1 %
Publication

33 Submitted to University of Strathclyde <1 %
Student Paper

| | | |
|----|---|------|
| 34 | docplayer.net Internet Source | <1 % |
| 35 | docslib.org Internet Source | <1 % |
| 36 | pubmed.ncbi.nlm.nih.gov Internet Source | <1 % |
| 37 | www.ijraset.com Internet Source | <1 % |
| 38 | Shelly C. Lu. "Antioxidants in the treatment of chronic liver diseases: Why is the efficacy evidence so weak in humans?", <i>Hepatology</i> , 2008 Publication | <1 % |
| 39 | assets.researchsquare.com Internet Source | <1 % |
| 40 | edoc.ub.uni-muenchen.de Internet Source | <1 % |
| 41 | link.springer.com Internet Source | <1 % |
| 42 | Buket Bulut Kocabas, Azade Attar, Selcen Ari Yuka, Melda Altikatoglu Yapaoz. "Biogenic Synthesis, Molecular Docking, Biomedical and Environmental Applications of Multifunctional CuO Nanoparticles mediated Phragmites australis", <i>Bioorganic Chemistry</i> , 2023 Publication | <1 % |

43

César R. García-Jacas, Yovani Marrero-Ponce, Fernando Cortés-Guzmán, José Suárez-Lezcano et al. "Enhancing Acute Oral Toxicity Predictions by using Consensus Modeling and Algebraic Form-Based 0D-to-2D Molecular Encodes", *Chemical Research in Toxicology*, 2019

Publication

<1 %

44

G. Krishnaswamy, P. Raghuram Shetty, B. Roopa, Salma Banu et al. "Synthesis, Characterization, PASS Prediction and in silico ADME Studies of Ester and Ether Linked 1,4-Disubstituted 1,2,3-Triazoles Derivatives via Click Approach", *Asian Journal of Chemistry*, 2020

Publication

<1 %

45

Hafsa Amat-ur-Rasool, Mehboob Ahmed, Shahida Hasnain, Abrar Ahmed, Wayne Grant Carter. "In Silico Design of Dual-Binding Site Anti-Cholinesterase Phytochemical Heterodimers as Treatment Options for Alzheimer's Disease", *Current Issues in Molecular Biology*, 2021

Publication

<1 %

46

Mary A. Okesola, Abayomi E. Adegboyega, Adewale J. Lasisi, Folasade A. Bello, Olubanke O. Ogunlana, Israel S. Afolabi. "Elucidating the interactions of bioactive compounds

<1 %

identified from *Camellia Sinensis* plant as promising candidates for the management of fibroids - A computational approach", *Informatics in Medicine Unlocked*, 2022

Publication

47

Subiyakto Rudi. "Public Policy in the Concept of Blue Economy for Anticipating Disasters in Indonesia", *BIO Web of Conferences*, 2023

Publication

<1 %

48

Violina T. Angelova, Tania Pencheva, Nikolay Vassilev, Elena K-Yovkova, Rositsa Mihaylova, Boris Petrov, Violeta Valcheva. "Development of New Antimycobacterial Sulfonyl Hydrazones and 4-Methyl-1,2,3-thiadiazole-Based Hydrazone Derivatives", *Antibiotics*, 2022

Publication

<1 %

49

ir.kdu.ac.lk

Internet Source

<1 %

50

jurnalfkip.unram.ac.id

Internet Source

<1 %

51

resources.qiagenbioinformatics.com

Internet Source

<1 %

52

www.ncbi.nlm.nih.gov

Internet Source

<1 %

53

Ethel Jeyaseela Jeyaraj, Yau Yan Lim, Wee Sim Choo. "Extraction methods of butterfly pea

<1 %

(Clitoria ternatea) flower and biological activities of its phytochemicals", Journal of Food Science and Technology, 2020

Publication

54

Ribi Ramadanti Multisona, Shwetali Shirodkar, Marcellus Arnold, Anna Gramza-Michalowska. "Clitoria ternatea Flower and Its Bioactive Compounds: Potential Use as Microencapsulated Ingredient for Functional Foods", Applied Sciences, 2023

Publication

<1 %

Exclude quotes Off

Exclude matches Off

Exclude bibliography Off

In Silico Pharmacokinetic and Toxicity Analysis on Clitoria Ternatea Flower

PAGE 1



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Verb This verb may be incorrect. Proofread the sentence to make sure you have used the correct form of the verb.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Article Error You may need to use an article before this word.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Article Error You may need to remove this article.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



P/V You have used the passive voice in this sentence. You may want to revise it using the active voice.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Confused You have used either an imprecise word or an incorrect word.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Article Error You may need to use an article before this word. Consider using the article **the**.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



P/V You have used the passive voice in this sentence. You may want to revise it using the active voice.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Possessive Review the rules for possessive nouns.



P/V You have used the passive voice in this sentence. You may want to revise it using the active voice.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Missing ", " Review the rules for using punctuation marks.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Wrong Form You may have used the wrong form of this word.



Wrong Form You may have used the wrong form of this word.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



P/V You have used the passive voice in this sentence. You may want to revise it using the active voice.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Wrong Article You may have used the wrong article or pronoun. Proofread the sentence to make sure that the article or pronoun agrees with the word it describes.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Prep. You may be using the wrong preposition.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



P/V You have used the passive voice in this sentence. You may want to revise it using the active voice.



P/V You have used the passive voice in this sentence. You may want to revise it using the active voice.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Missing ", " Review the rules for using punctuation marks.



Missing ", " Review the rules for using punctuation marks.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Missing ", " Review the rules for using punctuation marks.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Missing ", " Review the rules for using punctuation marks.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Missing ", " Review the rules for using punctuation marks.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Missing ", " Review the rules for using punctuation marks.



Missing ", " Review the rules for using punctuation marks.



Missing ", " Review the rules for using punctuation marks.



Missing ", " Review the rules for using punctuation marks.



Missing ", " Review the rules for using punctuation marks.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Missing ", " Review the rules for using punctuation marks.



Missing ", " Review the rules for using punctuation marks.



Missing ", " Review the rules for using punctuation marks.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Missing ", " Review the rules for using punctuation marks.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Article Error You may need to use an article before this word. Consider using the article **the**.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Wrong Article You may have used the wrong article or pronoun. Proofread the sentence to make sure that the article or pronoun agrees with the word it describes.



Verb This verb may be incorrect. Proofread the sentence to make sure you have used the correct form of the verb.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Possessive Review the rules for possessive nouns.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Proofread This part of the sentence contains an error or misspelling that makes your meaning unclear.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



P/V You have used the passive voice in this sentence. You may want to revise it using the active voice.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Article Error You may need to use an article before this word.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Article Error You may need to use an article before this word.



Missing ", " Review the rules for using punctuation marks.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Article Error You may need to remove this article.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Article Error You may need to use an article before this word. Consider using the article **the**.



P/V You have used the passive voice in this sentence. You may want to revise it using the active voice.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.

